The article presents current data on the effect of drugs for the treatment of gout on the composition and function of the intestinal microbiota. The potential possibilities of pre- and probiotics use for the prevention and complex therapy of gout are discussed, therapeutic effect may be associated with their impact on the uric acid synthesis and intestinal excretion, as well as with anti-inflammatory properties. The need for further research in this area is emphasized.

Lupus nephritis (LN) is the leading cause of death in systemic lupus erythematosus (SLE), so its early detection and treatment is of utmost importance. Features of the onset, clinical signs, certain morphological classes, as well as more aggressive therapy make it possible to assign SLE with LN to a distinct disease phenotype.

Objective: to characterize the clinical, immunological and morphological features of the SLE phenotype with a predominant kidney involvement based on a comparative analysis of patients with LN and without LN.

Patients and methods. The study included 400 patients with SLE who met the 2012 SLICC criteria and were hospitalized to V.A. Nasonova Research Institute of Rheumatology from 2013 to 2021. The diagnosis of LN was established in 192 (48%) patients, of which in 82 (43%) it was confirmed by pathological study of kidney biopsy specimens (the SLE group with LN). In 208 (52%) patients, no kidney damage was observed, and they constituted the SLE group without LN.

All patients underwent a standard examination with an assessment of disease activity according to the SLEDAI-2K index, irreversible changes in organs according to the SLICC damage index, immunological disorders, clinical and biochemical blood tests, urinalysis according to unified methods, glomerular filtration rate, as well as pathological examination of kidney biopsy specimens for confirmation of LN in the presence of an appropriate clinical picture. In patients of both groups, a comparative study of the main clinical, laboratory, immunological manifestations of SLE, the features of the disease onset, its first clinical signs, possible trigger factors, and the drugs used was carried out.

Results and discussion. In the LN group, insolation was more likely to trigger the development of SLE than in the group without LN (respectively, in 26% and 13% of cases; p=0.007). In turn, SLE without kidney damage more often than SLE with LN debuted during pregnancy or after childbirth.

The first signs of the disease in almost 40% of patients with LN were proteinuria and/or changes in urinary sediment, edema, increased blood pressure, the development of LN in some cases was preceded by polyarthritis or combined lesions of the skin and joints, but no later than 6 months, signs of kidney damage appeared. In the SLE group without LN, polyarthritis (in 33%), combined lesions of the skin and joints (in 26%), and Raynaud's syndrome (in 16%; p <0.0001) were more often observed at the onset. In patients with LN, erythematous lesions of the facial skin ("butterfly", in 42%), serositis (exudative pleuritis — in 44%, pericarditis — in 46%, ascites and hydrothorax — in 5%; p<0.0001), as well as hematological disorders such as anemia (in 63%), leukopenia (in 49%) and thrombocytopenia (in 42%) were present more frequently. With the development of LN, an acute course and high activity of the disease occurred significantly more often. In the study of immunological parameters in the group without LN, lupus anticoagulant (in 6%) and antibodies to SS-A/Ro and SS-B/La (in 18 and 9% of patients, respectively) were detected significantly more often, while in the LN group — hypocomplementemia (in 81%; p<0.0001). Therapy also differed significantly: patients with LN received higher doses of glucocorticoids (p<0.0001), mycophenolate mofetil, and cyclophosphamide.

Conclusion. SLE with LN can be considered a distinct disease phenotype with a set of characteristics (clinical and laboratory parameters, response to therapy, prognosis) that distinguish it from other SLE variants.

Objective: to analyze the subjective perception of the disease, coping behavior and adherence to treatment as parameters of psychological adaptation of patients with immunoinflammatory rheumatic diseases (IIRD).

Patients and methods. 163 women with IIRD who were on inpatient treatment were examined: 63 with systemic lupus erythematosus, 50 with rheumatoid arthritis, and 50 with systemic scleroderma. The mean age of the patients was 34.00±17.46 years.

Results and discussion. Groups of patients with different types of perception of the disease were identified: "Unformed perception of the disease" (group 1), "Positive perception of disease control" (group 2), "Negative perception of disease threat" (group 3). When comparing the three groups, it was found that in the group with an unformed perception of the disease, negative emotional experiences were less pronounced than in the other two groups. At the same time, the coping strategies "Self-control" and "Problem solving planning" were significantly higher in the group of patients who positively perceived the control of their disease.

Conclusion. Psychological adaptation of patients with IIRD depends on the type of perception of the disease. The identification of two basic profiles (“Disease threat perception” and “Disease and treatment control perception”) and three types of disease perception (“Unformed type of disease perception”, “Positive perception of disease control”, “Negative perception of the disease threat”) made it possible to obtain new, more differentiated ideas about the perception of the disease, which is the target of correctional psychological work with patients suffering from IIRD.

Currently, a large number of highly effective biologic disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are used for the treatment of rheumatoid arthritis (RA). However, in addition to effectiveness, it is necessary to evaluate the risk of adverse events (AEs) when using them.

Objective: to determine the predictors of bDMARDs and tsDMARDs discontinuation due to AEs in patients with RA.

Patients and methods. The study included 661 patients with RA who took bDMARDs and tsDMARDs. The search for predictors of targeted therapy discontinuation due to AEs was carried out in two stages. At the first stage, using the Kaplan-Meier method, we selected indicators that showed the greatest significant single-factor relationship with the duration of retention on therapy. At the second stage, significant independent indicators were obtained by iterative selection of variables within the multivariate proportional risk model according to Cox.

Results and discussion. The presence of rheumatoid nodules (p<0.001), high doses of glucocorticoids (GC; p<0.001), low doses of methotrexate (MT; p=0.009) are significant independent factors for increasing the risk of drugs discontinuation due to the development of AEs. The type of bDMARDs/tsDMARD used also significantly correlated with the risk of discontinuation of therapy due to AEs. A relatively high risk of treatment discontinuation was observed with infliximab (IFN) and certolizumab pegol (CZP). Cancellation of IFN was associated with the occurrence of infusion reactions and infectious complications, and CZP was associated with infectious complications.

Conclusion. An increase in the dose of MT and decrease in the use of GCs can help prevent the development of AEs leading to the abolition of biologics and tsDMARDs. Significant differences were found between bDMARDs in terms of the risk of their cancellation due to AEs.

Evaluation of the reasons for discontinuation of therapy with Janus kinase inhibitors (JAKi) may provide a clue to their more effective use.

Objective : to analyze the survival of tofacitinib (TOFA) therapy and the reasons for its discontinuation in rheumatoid arthritis (RA) in real clinical practice.

Patients and methods. The study included 30 adult patients with RA hospitalized to the V.A. Nasonova Research Institute of Rheumatology from 2018 to 2020 for the biologic disease modifying antirheumatic drugs (bDMARDs) or JAKi treatment. Patients were followed up for 3 years or until treatment with TOFA was discontinued, whichever occurred first.

Results and discussion. TOFA was prescribed as the first line therapy in 3 patients. In all these patients, the drug was discontinued for the following reasons: insufficient efficacy (IE) after 2 full years of treatment; adverse reaction (AR); administrative reasons (AdR), i.e. the inability to continue therapy due to the lack of drug supply at the place of residence. 11 patients received TOFA as the second line therapy, in 8 of them the treatment was interrupted: in 4 due to IE, in 3 due to AR (skin allergy) and in 1 due to AdR one year after its initiation. TOFA was prescribed as a third line therapy in 9 patients, in 2 of them the drug was discontinued due to IE and in 3 due to AR (allergic dermatitis in 2, dyspepsia in 1). Another 1 patient refused treatment due to a planned pregnancy. 6 patients received TOFA as the fourth line therapy, 5 of them (83.3%) continued to receive it for more than 3 years. In 1 patient, TOFA was discontinued after 1 month due to the dry cough and shortness of breath onset. In another 1 patient who was prescribed TOFA as the fifth line therapy, treatment was discontinued due to AR (recurrent Herpes zoster).

Conclusion. As the results of the study show, no relationship was found between the incidence of AR or IE and clinical and demographic indicators, as well as the frequency of TOFA withdrawal and the line of therapy. At the same time, the shortest duration of retention on TOFA therapy was noted when it was prescribed as a first-line drug.

Background. Rheumatoid arthritis (RA) is a common chronic autoimmune disorder that has a female predominance and commonly affects women of childbearing age. It is shown to remit during pregnancy in most studies and improve in about half of the patients when assessed with objective disease activity measures.

Objective — to assess the pregnancy outcomes in women with RA prior and after the diagnosis and compare them with those in women with no chronic illness, to evaluate contraceptive practices and contraceptive method efficacy with the use of concomitant rheumatic medications (methotrexate, leflunomide).

Patients and Methods. Female patients diagnosed with RA according to ACR/EULAR 2010 classification criteria were compared with apparently healthy female controls matching in age in this case-control study. Data were collected by questionnaires and interviews. The questionnaires included demographic data and pregnancy outcomes, mode of delivery, contraceptive methods used by patients against the background of methotrexate and leflunomide therapy.

Results and discussion. One hundred patients with RA were included. The mean age of the patients and controls was 38.4±5.1 and 36.7±4.5 years, respectively. The live births significantly decreased in female patients with RA compared to the controls and the period before the diagnosis (p=0.01, p=0.002, respectively). Caesarean section frequency was higher in the control group compared to patients with RA (p=0.001). But in patients with RA, frequency of caesarean section increased after the diagnosis (p=0.021). Frequency of unplanned pregnancy significantly decreased after the diagnosis of RA compared to the period before the diagnosis (p<0.001). About 75.4% of patients had the desired number of children in their family before the diagnosis, and 24.6% feared the effect of RA on themselves and their children. 81% of 100 women with RA used methotrexate, 43.2% of them received rheumatological consultation regarding the contraceptive methods, and 56.8% did not. 30.86% of patients treated with methotrexate used ineffective contraceptive methods, 27.16% — long-acting reversible methods, 14.81% — effective contraceptive methods, and 24.69% did not use any contraceptive methods. 19% of RA patients used leflunomide, and 73.7% of them received rheumatological consultation regarding the type of contraceptive methods, 36.84% used effective methods of contraception, 31.58% — long-acting reversible methods, 15.79% — ineffective contraceptive methods and 15.79% did not use any contraceptive methods.

Conclusion. There is a decrease in live births and an increase in preterm birth frequency as well as caesarean sections in Iraqi female patients with RA. There is lack of knowledge about the importance of contraceptive methods efficacy in relation to teratogenic medications (methotrexate, and leflunomide).

The mechanism of osteoporosis (OP) development in systemic sclerosis (SSc) remains unclear.

Objective: to assess bone mineral density (BMD) and the level of bone metabolism markers (osteocalcin — OC, — C-terminal type I collagen telopeptides — b-CrossLaps) in the blood serum of patients with SSc.

Patients and methods. 65 patients with SSc were examined, 6 (9%) men and 59 (91%) women, the average age was 51 [39; 61] year (main group), and 35 healthy individuals comparable in anthropometric parameters (control group). In all individuals were assessed the most important populational risk factors for OP. BMD was determined using dual energy X-ray absorptiometry (DXA); the level of vitamin D, OC and b-CrossLaps in blood serum — by enzyme immunoassay.

Results and discussion. A decrease in BMD was statistically significantly more common in patients with SSc (46, 71%), than in controls (11, 31%). Significant risk factors for OP in SSc were early menopause, low physical activity, hypovitaminosis D, and probably high activity and duration of the disease. In patients with SSc, there was a significant decrease in the level of OC compared with the controls; in patients with a reduced BMD, the content of OC was significantly less than in patients with normal BMD. The average values of b-CrossLaps in the main and control groups were comparable, but in patients with OP this parameter was lower than in those with normal BMD.

Conclusion. In patients with SSc, OP develops statistically significantly more often than in healthy individuals. Risk factors for OP are early menopause, low physical activity, long duration and high activity of SSc. The predominance of bone formation impairment over bone resorption as a mechanism for the development of secondary OP was noted.

Patellofemoral pain syndrome (PFPS, patellar chondromalacia) after knee surgery is an important problem in sports medicine, solutions to which have not been developed enough.

Objective: to determine the effect of complex treatment using an injectable chondroprotector and special exercise therapy on the functional state, statokinetic stability and severity of PFPS in athletes after reconstruction of the anterior cruciate ligament (ACL) of the knee joint.

Patients and methods. An observational randomized controlled trial included 40 athletes after ACL reconstruction. The patients were divided into two groups. In the control group (n=20), a special rehabilitation technique was used after ACL reconstruction. In the main group (n=20), along with a similar method of rehabilitation, patients received a course of intramuscular injections of Alflutop (1 ml, No. 20). The duration of rehabilitation treatment was 1 month.

Pain was assessed using a numerical rating scale and knee joint function using the Kujala questionnaire, statokinetic stability was assessed before and after complex rehabilitation treatment.

Results and discussion. One month after the start of rehabilitation measures, both groups showed a significant decrease in pain intensity and an improvement in the functional state of the knee joint according to the Kujala questionnaire. The study of statokinetic stability indicators showed that after the course of rehabilitation in both groups, when standing with open eyes, there was a decrease in the area of the common center of pressure — CCOP (p<0.05) and an improvement in statokinetic stability, and when standing with eyes closed, a decrease in the CCOP area (p<0.05). At the same time, the difference in the results before and after the course of rehabilitation in the main group was significantly greater than in the control (p<0.05). The speed of the CCOP movement with open eyes in both groups did not change significantly: when standing with eyes closed, its positive dynamics was revealed after the course of rehabilitation (p<0.05).

Conclusion. Intramuscular SYSADOA injection therapy, which was used as part of a rehabilitation program, reduced pain and improved the function of the knee joint and had a positive effect on statokinetic stability in athletes after ACL reconstruction.

Objective: to study the morphological reflection of the parenteral form of highly purified chondroitin sulfate (CS) action in patients with osteoarthritis (OA) of the knee joints (KJ) during total knee arthroplasty (TA).

Patients and methods. An open, prospective, controlled, randomized study included 67 patients (24 men and 43 women aged 41—73 years) with stage III knee OA and grade 2 functional insufficiency. The 1st (control) group included 35 patients, the 2nd (main) group included 32 patients. At baseline of the study, all patients were taking non-steroidal anti-inflammatory drugs (NSAIDs) at a standard daily dose. Patients of the 2nd group 2 months before the TA of KJ, additionally received a parenteral form of CS (Honrogard®), intramuscularly every other day: the first 3 injections at a dose of 100 mg/day; and if tolerability was good starting from the 4th injection, at a dose of200 mg / day (course — 25 injections). The intensity of pain was assessed according to the visual analog scale, WOMAC index, functional status according to the KOOS (Knee and Osteoarthritis Outcome Score) scale and the Lequesne index, standard radiography and magnetic resonance imaging of the knee joint were performed with an assessment of the T2 relaxation time. TA KJ was carried out according to C. Ranawat method.

Results and discussion. In contrast to patients who took only NSAIDs, in patients who received CS during 50 days within 2 months before surgery, there were signs of adaptive restructuring in all layers of the preserved volume of hyaline cartilage and a decrease in the synovial membrane inflammation at the time of TA of KJ.

Conclusion. The obtained results allow us to recommend the use of the parenteral form of CS (Honrogard®) according to the described scheme within 2 months before the TA of KJ in order to improve the morphological characteristics of cartilage and synovial tissue in the joints of the contralateral lower limb, taking into account the increase in the load on it in the postoperative period.

Objective: to evaluate the effectiveness of therapy with AMBENE®Bio (AB) in comparison with the comparator drug (bioactive concentrate of small marine fish, BCSMF) in patients with osteoarthritis (OA) of large and small joints in routine clinical practice.

Patients and methods. KOLIBRI multicenter, observational, non-randomized, comparative study included 233 patients with OA of the small hand joints (HJ) or knee joints (KJ) from three Russian centers (two in Moscow and one in Tula). Patients with a generalized form of OA were excluded from the analysis. The remaining patients were divided into two groups depending on the localization of OA. The first group included 174 patients with knee OA, 105 of them received AB, and 69 received the reference drug (BCSMF) according to the same regimen. The second group consisted of 21 women with HJ OA: 13 patients were prescribed AB, and 8 — the reference drug.

The duration of the study averaged 330±14 days, the total number of visits was 4. The main indicator of effectiveness was the dynamics of pain during movement according to VAS (0—100 mm) 30±7 days after the start of treatment compared with the baseline value. All patients underwent radiography of the HJ and KJ, as well as ultrasound of the involved joints.

Results and discussion. Both drugs provided significant clinical improvement in patients with OA, which is consistent with other studies with similar design and long follow-up. These data confirm the symptom-modifying properties of the presented group of combined drugs in the OA treatment. The Russian injectable drug AB in OA was not inferior in effectiveness to the foreign BCSMF. According to the OMERACT-OARSI criteria, 85.2% and 88.9% of patients, respectively, responded to treatment with AB and the reference drug. In both groups, half of the patients managed to stop further use of non-steroidal anti-inflammatory drugs (NSAIDs) on a regular basis.

Conclusion. The use of AB was accompanied not only by a decrease in the severity of clinical symptoms of OA, but also by a decrease in the daily requirement for NSAIDs almost by 2 times.

Objective: to confirm the efficacy and safety of levilimab in patients with rheumatoid arthritis (RA) switched from other interleukin 6 receptor inhibitors (iIL6R) for non-medical reasons.

Patients and methods. A retrospective analysis of data from the register of patients with RA who during the COVID-19 pandemic were switched from foreign iIL6Rs to the Russian drug levilimab. Treatment regimens with levilimab in combination with synthetic diseasemodifying antirheumatic drugs (sDMARDs) and/or glucocorticoids (GCs) were used, as well as a monotherapy regimen in case of DMARDs intolerance.

Results and discussion. In 150 patients with RA, a successful non-medical switch to levilimab was demonstrated with the preservation and intensification of the clinical effect achieved on previous therapy with iIL6R. After switching to levilimab, the DAS28-CRP index decreased by an average of 0.098 at 3 months and by 0.25 at 6 months (p=0.214 for both time points). There was a decrease in the proportion of patients with elevated levels of CRP, as well as with high RA activity. In a number of patients who showed high efficacy of levilimab, it became possible to reduce the dose or number of DMARDs, as well as cease GCs intake. Good tolerability and a favorable safety profile of levilimab were noted, including in relation to the new coronavirus infection that developed during therapy.

Conclusion. Therapy with Russian iIL6R levilimab is effective and safe, including in patients switched from other drugs for non-medical reasons, as well as in relation to the novel coronavirus infection that developed during therapy.

In December 2019, the world faced a new infectious disease, called the novel coronavirus disease 2019 (COVID-19), whose spread has become pandemic. The infection that remains with us to the present day can cause very severe respiratory symptoms up to total lung damage and death, as well as serious systemic manifestations associated with excessive activation of immune mechanisms. Currently, there are many cases of secondary autoimmune processes, often forming full-fledged autoimmune diseases, in people who have had a new coronavirus infection.

We present a clinical observation of episcleritis developed on the background of COVID-19, and then an articular syndrome onset that met the classification criteria for rheumatoid arthritis. The unusual debut of the articular syndrome in this patient, the difficulties of early diagnosis of the disease, as well as possible mechanisms of the formation of such associations are discussed.

This article describes a case of a transformed diffuse large B-cell lymphoma of the stomach in a patient with Sjögren's disease (SjD) and systemic sclerosis (SSc), as well as a brief review of the literature on lymphoproliferative diseases in SjD and SSc.

The tumor necrosis factor-а inhibitor etanercept (ETC) is one of the most popular members of the group of biologic disease-modifying antirheumatic drugs used for treatment of immune-mediated inflammatory rheumatic diseases (IRD). According to a series of double-blind randomized controlled trials (RCTs) and related meta-analyses, the use of ETC in combination with methotrexate and as monotherapy allows to achieve a significant reduction in the activity of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). ETC is fastacting and provides a significant reduction in the most debilitating manifestations of IRD, such as pain, dysfunction and fatigue. ETC has a relatively low risk of developing serious infections.

In 2017, the European Medical Agency registered a new ETC biosimilar (Erelzy®) for the treatment of RA, PsA, plaque psoriasis, AS, axial spondyloarthritis and juvenile idiopathic arthritis. This drug has been extensively tested in two large RCTs, EGALITY (n=531) and EQUIRA (n=376), comparing its efficacy and safety with a reference ETC (rETC) in patients with active psoriasis and RA. These studies showed that biosimilar did not differ from rETC in terms of therapeutic potential, risk of complications and immunogenicity, and switching from rETC to biosimilar did not lead to a decrease in the effectiveness and tolerability of therapy. In both RCTs, the new ETC biosimilar, in which the citrate buffer forms the basis of its solution, demonstrated a statistically significantly lower number of local post-injection complications (pain, hyperemia) than rETC, which contains phosphate buffer: 4.9 and 6.5% versus 14.2 and 18 .4% respectively.

Osteoarthritis is the most common rheumatic disease, accompanied by constant pain and dysfunction of the joints, the progression of which leads to a deterioration in the quality of life and often to disability of patients. The article presents the prevalence, predictors of development and progression of osteoarthritis of the hand joints (OHJ). Clinical classification of OHJ, clinical picture depending on the localization of the process, topical features of involvement of the hand joints in different types of OHJ are given. Clinical, laboratory and instrumental methods for diagnosing of the disease, classification and diagnostic criteria are described, much attention is paid to modern principles of OHJ therapy in accordance with Russian clinical guidelines, as well as EULAR and ACR recommendations.

Osteoarthritis (OA) is the most common joint disease due to the increasing life expectancy of the world's population. Every 2nd patient over the age of 50 suffers from knee or hip OA, and this is directly related to the increased burden on healthcare. Accumulated data on the comorbid profile of patients with OA dictate the need to identify disease phenotypes in order to provide personalized care. Individual clinical manifestations of OA also require a differential approach: the pain treatment requires consideration of the patient's psycho-emotional profile and the possibility of involving nociceptive pathways in the process. However, due to the ambiguity of existing clinical guidelines, most experts note a number of difficulties in prescribing treatment for patients with OA.

The resolution presents an agreed opinion of experts on the algorithms for managing patients with OA, starting from the primary level, with the gradual involvement of related specialists. Some issues of a personalized approach are considered depending on the presence of comorbid pathology and the severity of individual symptoms of the disease. The prospects of the combined use of pharmacological and non-drug methods of treatment are noted; emphasis was placed on the importance of rehabilitation measures at the first level of medical care, provided to patients with OA, long before the development of structural changes.

The proposed algorithms for managing patients can be considered as the basis for future recommendations for managing patients with this pathology.